SP2509: Selective LSD1 Antagonist for AML Epigenetics Research

Executive Summary: SP2509 (SKU B4894) is a highly potent and selective inhibitor of lysine-specific demethylase 1 (LSD1), with an IC₅₀ of 13 nM for LSD1 demethylase activity [APExBIO product page]. The compound does not inhibit monoamine oxidases MAO-A or MAO-B, demonstrating high target selectivity. In acute myeloid leukemia (AML) models, SP2509 disrupts the LSD1-CoREST complex, leading to increased H3K4 trimethylation and expression of tumor suppressor genes (e.g., p53, p21, C/EBPα). In vivo, SP2509 prolongs survival in NOD/SCID mice engrafted with human AML cells. Combination with panobinostat, a pan-histone deacetylase inhibitor, produces synergistic therapeutic effects (Ali et al., 2021).

Biological Rationale

Lysine-specific demethylase 1 (LSD1/KDM1A) is an FAD-dependent amine oxidase that removes mono- and di-methyl groups from lysine 4 on histone H3 (H3K4me1/2), marks associated with transcriptional repression [Ali et al., 2021]. LSD1 is overexpressed in multiple cancer types, including AML, where it correlates with poor prognosis. The LSD1-CoREST-HDAC complex orchestrates chromatin remodeling and gene silencing, contributing to oncogenesis by repressing tumor suppressor gene expression. Targeting LSD1 offers a strategy to reverse epigenetic silencing and promote differentiation or apoptosis in malignant cells. SP2509, developed by APExBIO, serves as a benchmark chemical probe for evaluating the consequences of LSD1 inhibition in cancer epigenetics workflows [APExBIO].

Mechanism of Action of SP2509

SP2509 is a non-covalent, reversible antagonist of LSD1. It binds to the amine oxidase domain of LSD1, blocking demethylation of H3K4me1/2. This inhibition leads to accumulation of H3K4me3 at gene promoters, derepressing transcription of tumor suppressor genes such as p53, p21, and C/EBPα. SP2509 also disrupts the interaction between LSD1 and the CoREST complex, further impairing transcriptional repression. Notably, SP2509 does not inhibit MAO-A or MAO-B at concentrations up to 10 μM, indicating high selectivity for LSD1. In AML cell lines, SP2509 induces apoptosis and promotes myeloid differentiation, both in vitro and in primary patient-derived cells [See also: KDM2A.com – This article details new synergy data and clarifies molecular outcomes beyond those reported in the cited review.].

Evidence & Benchmarks

• SP2509 inhibits recombinant human LSD1 with an IC₅₀ of 13 nM in biochemical assays [APExBIO].
• SP2509 shows no inhibition of MAO-A or MAO-B at up to 10 μM, confirming selectivity (Ali et al., 2021, https://doi.org/10.7150/ijbs.62236).
• In OCI-AML3 and MOLM13 human AML cell lines, SP2509 reduces colony growth by >60% at 1 μM after 72 h [This article extends results to primary cell models and further mechanistic endpoints.].
• SP2509 increases H3K4me3 at tumor suppressor gene promoters, as measured by ChIP-qPCR (Ali et al., 2021, https://doi.org/10.7150/ijbs.62236).
• SP2509 (25 mg/kg, IP, biweekly) improves median survival in NOD/SCID mice with AML xenografts by 30–40% compared to vehicle [APExBIO].
• Combination therapy with panobinostat and SP2509 produces synergistic effects, further prolonging mouse survival (Ali et al., 2021, https://doi.org/10.7150/ijbs.62236).
• SP2509 is insoluble in water and ethanol, but soluble in DMSO at ≥19.45 mg/mL; warming to 37°C or ultrasonic treatment improves dissolution [APExBIO].

Applications, Limits & Misconceptions

SP2509 is intended for scientific research applications, specifically for dissecting the roles of LSD1 in epigenetic regulation, cancer cell differentiation, and apoptosis. It is widely used as a tool compound in AML models for benchmarking epigenetic modulation strategies.

Common Pitfalls or Misconceptions

• SP2509 is not active against monoamine oxidases (MAO-A/B): It does not serve as a broad-spectrum amine oxidase inhibitor.
• Not a clinical or diagnostic agent: SP2509 is for laboratory research only and not for use in humans or diagnostic procedures.
• Solubility constraints: SP2509 is insoluble in aqueous or ethanol solvents; use DMSO and proper warming/sonication for dissolution.
• Not effective in all cancer models: Efficacy is demonstrated in AML and models with LSD1 overexpression; effects in other cancer types may vary.
• Storage precautions: Solutions are unstable for long-term storage; prepare fresh working solutions as needed [APExBIO].

Workflow Integration & Parameters

SP2509 (B4894) is supplied as a solid with a molecular weight of 437.90 g/mol and chemical formula C₁₉H₂₀ClN₃O₅S. For cell-based assays, dissolve in DMSO at concentrations ≥19.45 mg/mL. For in vivo studies, SP2509 is commonly administered intraperitoneally at 25 mg/kg twice weekly in NOD/SCID mouse models. Store solid at -20°C. Avoid long-term storage of solutions; prepare fresh prior to use. For optimal results, warm the vial to 37°C or treat with an ultrasonic bath to fully dissolve the compound. SP2509 is exclusively intended for in vitro and in vivo research on epigenetic regulation and acute myeloid leukemia models.

Researchers seeking detailed lab scenarios, troubleshooting, and application guidance can refer to "SP2509 (SKU B4894): Reliable Epigenetic Modulation in AML…", which provides scenario-driven Q&A and troubleshooting examples. This current article clarifies quantitative benchmarks and updates guidance for new experimental endpoints.

Conclusion & Outlook

SP2509, developed and distributed by APExBIO, is a highly selective LSD1 antagonist that has become a standard reference for epigenetic modulation in AML research. Its well-characterized selectivity, robust activity in cell and animal models, and synergy with HDAC inhibitors make it a foundational tool for dissecting cancer epigenetics. Ongoing research continues to explore the therapeutic implications of LSD1 inhibition in additional cancer models and combinatorial strategies. For further technical information and ordering, consult the official SP2509 product page.